8-K: OmniAb Reports Q1 2025 Financial Results, Affirms Revenue Guidance, and Launches xPloration Partner Access Program

OmniAb announces its Q1 2025 financial results, highlighting revenue growth, reduced operating expenses, and the launch of a new partner program.

Summary

• OmniAb reported first quarter 2025 revenue of $4.2 million, an increase from $3.8 million in the same period of 2024.
• The revenue increase was primarily driven by a $1.0 million Phase 1 milestone payment and higher license fees, offset by lower service revenue.
• Research and development expenses decreased to $12.6 million from $14.6 million year-over-year, due to lower share-based compensation and external expenses.
• General and administrative expenses also decreased to $7.9 million from $8.3 million year-over-year, primarily due to lower legal fees and share-based compensation.
• Net loss for the quarter was $18.2 million, or $0.17 per share, compared to a net loss of $19.0 million, or $0.19 per share, in the first quarter of 2024.
• As of March 31, 2025, OmniAb had $43.6 million in cash, cash equivalents, and short-term investments.
• OmniAb affirmed its 2025 revenue guidance of $20 million to $25 million and revised its operating expense guidance to $85 million to $90 million.
• The company expects 2025 cash use to be lower than the $38.9 million used in 2024, excluding the 2024 ATM issuance.
• OmniAb entered into three new platform license agreements and a research collaboration with Orion Corporation, which includes a $250,000 upfront payment and potential milestones exceeding $55 million.
• Post-quarter, OmniAb entered into an asset-based sale with Angelini Pharma for a small molecule Kv7.2 program, receiving $3 million upfront and potential milestones over $170 million.
• The company launched the xPloration Partner Access Program, offering a high-throughput single B-cell screening instrument.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is still operating at a loss, revenue is up, expenses are down, and they are reaffirming guidance. New partnerships and the xPloration program launch are also positive indicators.

Positives

• Revenue increased in Q1 2025 compared to Q1 2024.
• Operating expenses decreased in Q1 2025 compared to Q1 2024.
• Net loss decreased in Q1 2025 compared to Q1 2024.
• The company affirmed its 2025 revenue guidance.
• Operating expense guidance was revised downwards, indicating improved efficiency.
• OmniAb entered into new partnerships and collaborations with potential for significant milestone payments.
• The launch of the xPloration Partner Access Program could drive future revenue and cash flow.
• The company expects 2025 cash use to be lower than in 2024.

Negatives

• The company reported a net loss of $18.2 million for Q1 2025.
• Service revenue was lower compared to the same period in 2024.

Risks

• The company's future success depends on the acceptance of its technology platform by new and existing partners.
• Biopharmaceutical development is inherently uncertain, and the company has no control over the development plans, regulatory strategies, or commercialization efforts of its partners.
• Changes in technology and the competitive environment in the life sciences and biotechnology platform market could pose risks.
• The company relies on a limited number of third-party manufacturers and suppliers for its xPloration instruments and related consumables.
• Unstable market and economic conditions may have serious adverse consequences on the company's business, financial condition, and stock price.

Future Outlook

OmniAb affirms its 2025 revenue guidance of $20 million to $25 million and revises its operating expense guidance to $85 million to $90 million. The company expects 2025 cash use to be lower than in 2024.

Management Comments

• Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts, said Matt Foehr, Chief Executive Officer of OmniAb.
• Today we announced the xPloration Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportunities that we believe will be accretive to both earnings and cash flow in shortand long-term.
• As we look ahead, our 2025 outlook remains on track with our commitment to running an efficient and leverageable business.

Industry Context

OmniAb operates in the competitive biopharmaceutical industry, providing technology platforms for antibody discovery. The launch of the xPloration Partner Access Program and new partnerships aim to strengthen its position in the market.

Comparison to Industry Standards

• It's difficult to directly compare OmniAb's results to industry standards without knowing the specific details of their agreements and the performance of their partners' programs.
• However, companies like Ligand Pharmaceuticals and AbCellera Biologics also operate in the antibody discovery space and have similar business models involving upfront fees, milestones, and royalties.
• Ligand Pharmaceuticals reported total revenues of $76.4 million for Q1 2024, significantly higher than OmniAb's $4.2 million, but Ligand has a more diversified portfolio of assets.
• AbCellera Biologics reported revenue of $10.1 million for Q1 2024, which is also higher than OmniAb's revenue.
• The success of OmniAb's partners' programs, such as those involving Immunovant and CStone Pharmaceuticals, will be crucial for driving future revenue through milestone payments and royalties.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and future outlook provide information for investment decisions.
• Partners: The xPloration Partner Access Program and new collaborations offer opportunities for advancing their research and development efforts.
• Employees: The company's performance and strategic initiatives impact job security and growth opportunities.
• Customers: The development of new therapeutics through OmniAb's technology could lead to improved treatment options.

Next Steps

• OmniAb will showcase xPloration at the 21st Annual PEGS Boston Summit (May 12-16, 2025).
• Multiple partners will be presenting data from programs developed with OmniAb technology at the American Society of Clinical Oncology Annual Meeting (May 30 June 3, 2025).
• Immunovant expects to announce additional data for batoclimab in GD, including six-month remission data, this summer.
• Immunovant expects top-line results for batoclimab from potentially registrational Phase 3 trials in thyroid eye disease in the second half of 2025.

Key Dates

Keywords

OmniAb, financial results, Q1 2025, revenue, operating expenses, net loss, guidance, xPloration, partner program, antibody discovery, biopharmaceutical, milestone payments, license agreements